Personalized cancer vaccine may increase long-term survival in patients with deadly brain cancer

An international Phase III study led by researchers at UCLA and at Northwest Biotherapeutics, Inc. has found that a personalized glioblastoma vaccine may increase long-term survival in some patients. Nearly 30 percent of patients in the current trial have now survived at least three years post-enrollment, with patients continuing to be followed over time.

The vaccine, known as DCVax-L, uses a patient's own dendritic cells to help activate the immune system to fight cancer. Currently, median survival for glioblastoma is 15 to 17 months, and less than 5 percent of glioblastoma patients who receive standard care survive five years.

The interim findings from the study, which is still in progress, were published May 29 in the Journal of Translational Medicine. The study is the largest trial to date testing a customized vaccine in patients diagnosed with the deadly brain cancer.

"The survival rate is quite remarkable compared to what would be expected for glioblastoma," said lead author Dr. Linda Liau, chair of the neurosurgery department at the David Geffen School of Medicine at UCLA and a member of the UCLA Jonsson Comprehensive Cancer Center. "What's particularly impressive about immunotherapy trials is that there seems to be a population of about 20 to 30 percent of patients who are living significantly longer than expected - the long tail of the survival curve. And those are the people in whom we think there may be a particularly strong immune response against their cancer that is protecting them from getting tumor reoccurrence."

The vaccine was administered in newly diagnosed glioblastoma patients -- at 80 sites across the globe -- from July 2007 through November 2015. All patients underwent standard care therapy (surgery to resect the tumor, followed by chemoradiotherapy) before participating in the trial.

After standard care therapy, patients were randomized into two arms of the trial. The first group (232 patients) continued to receive standard care and DCVax-L; the second group (99 patients) received standard care and a placebo treatment. All patients were allowed to receive the vaccine following tumor progression or recurrence. Due to the crossover design of the trial, nearly 90 percent of the patients received the vaccine.

Researchers found that when analyzing all the patients in both arms of the trial (i.e., the intent to treat population), median survival is 23.1 months, which is eight months longer than the current median survival time from historical studies using standard of care chemoradiation alone.

Of those who were enrolled more than three years before the data analysis date of this publication, 67 patients (30 percent of the total) survived for more than 30 months, and 44 (24.2 percent) survived for more than 36 months. These patients are expected to have a median survival of 46.5 to 88.2 months. At the time of the analysis, 108 of the 331 patients enrolled in the trial (32.6 percent) were still alive.

Researchers at UCLA have spent almost two decades working to activate dendritic cells against brain cancer. Dendritic cells are a type of white blood cell that typically alerts the immune system when it detects a foreign invader. Liau and her team were the first to test a dendritic cell-based vaccine in patients with glioblastoma, a type of tumor that had previously been thought to be immune-privileged, meaning the immune system won't attack it. However, Liau and her colleagues were able to demonstrate in previous studies that the body could actually mount an immune response against tumors in the brain following the vaccination.

"The unique thing about the DCVax-L vaccine is that this doesn't target a single antigen," Liau said. "This treatment actually uses the patient's own tumor specimen to make the vaccine. This is really a form of personalized immunotherapy that is customized to an individual patient and his/her tumor." The vaccine works by combining brain tumor tissue lysate removed during a patient's surgery with dendritic immune cells drawn from his or her blood. The dendritic cells are activated in the lab to turn against the tumor cells and then injected back into the patient, activating his or her T cells to attack the tumor. In short, the vaccine teaches the immune system to battle the cancer.

Because patients on the trial are living longer than what has been historically expected, the study groups are still blinded and researchers are continuing to monitor the patients to assess the ultimate difference in long-term survival. At that point, they'll issue a final report.

Liau and her colleagues are also in the process of developing new therapies that combine the vaccine and other treatments, with new clinical trials expected to be open in the near future.

Research reported in the Journal of Translational Medicine was supported by Northwest Biotherapeutics, Inc. and the UCLA SPORE in Brain Cancer.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walpert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6.

Most Popular Now

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

AstraZeneca launches call for entries to the 2023 …

AstraZeneca has announced the launch of the 2023 R&D Postdoctoral Challenge, an initiative designed to accelerate ideas to transform the treatment of some of the world’s ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

DNA treatment could delay paralysis that strikes n…

In virtually all persons with amyotrophic lateral sclerosis (ALS) and in up to half of all cases of Alzheimer's disease (AD) and frontotemporal dementia, a protein called...

Novartis Tafinlar + Mekinist approved by FDA for p…

Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric p...